학술논문
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Document Type
Article
Author
Source
Subject
*COVID-19
*LYMPHOPENIA
*COVID-19 pandemic
*MULTIPLE sclerosis
*INFLAMMATION
*LYMPHOCYTE count
*
*
*
*
*
Language
ISSN
1352-4585
Abstract
Background: Most cases of COVID-19 are considered mild, but patients with immunosuppressant treatment might be prone to severe courses of disease. Expert panels advise to delay treatment with cell-depleting MS therapies during the COVID-19 pandemic. Methods: We report a case of a patient with relapsing-remitting multiple sclerosis who developed COVID-19 pneumonia 2 weeks after the first week of cladribine therapy. Results: Despite a severe lymphopenia (absolute lymphocyte count 240/µL), the patient had a moderate course of COVID-19. Conclusion: Apart from maximal supportive treatment, this could be due to cladribine reducing inflammatory response, which probably contributes considerably to severe courses of COVID-19 pneumonia. [ABSTRACT FROM AUTHOR]